Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.10 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including other brain neurons; strongest in somatotrophs | 0.75 |
| chemistry Open Targets | compounds already reach it: macimorelin, ibutamoren mesylate, relamorelin +9 | 1.00 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 1 stopped | 0.20 |
| literature PubMed | 10 Parkinson's papers of 1,420 | 0.69 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 2610
Sealed predictions
- GHSR in dopamine neurons, braak+0.46 (p 0.209) → +0.57 (p 0.108)receipt 2616
Swarm cases
receipt 2616: GHSR in dopamine neurons, braak
- power
- full sample +0.59 (p 0.011, n 18), 95% CI +0.16 to +0.83. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.58 (p 0.013, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.58 (p 0.013, n 18). not the mix.
- skeptic
- leave-one-out range +0.53 to +0.66, sign flips 0; without severely affected donors +0.59 (p 0.011, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for GHSR in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts